The answer, first
The answer, first. A place on the WADA Prohibited List is not evidence that a compound works.
Section S0 prohibits, at all times, any pharmacological substance with no current approval by any governmental regulatory health authority for human therapeutic use — the trigger is the missing approval, not a demonstrated effect, and that precaution is the entire design.
BPC-157 became the first substance ever written into S0 as a named example on the 2022 List, and USADA's own page on it states there are no human clinical trials establishing efficacy for the use of BPC-157 for any diagnosis or treatment4.
Both are true at the same time, and anyone selling you the ban as proof has skipped the sentence in between.
What the anti-doping file does establish is different, and still worth having: laboratories have built and validated urine assays for BPC-157 down to 0.1 ng/mL, for the seven-residue fragment sold as TB-500, and for the metabolites of five growth-hormone-releasing peptides.
Sport paid for the chemistry to catch compounds medicine never paid for a trial to test. That asymmetry is the signal — a signal about attention, incentive and belief, not about efficacy.
- S0 bans by category, not by evidence. Any pharmacological substance with no current approval anywhere for human therapeutic use is prohibited at all times. Efficacy is not a criterion for inclusion, which is why banned therefore it works is a broken inference before it starts.
- WADA's own List does not claim its contents work. A 2019 review in Sports Medicine assessed all 23 substance classes and found only five with double-blind randomised evidence of enhancing actual sports performance in trained subjects. For eleven classes, no well-designed studies existed at all20.
- Sport's chemistry file is genuinely deep, and it is public. Validated methods exist for BPC-157 in human urine at 0.1 ng/mL, for Ac-LKKTETQ isolated out of a TB-500 product, for the urinary metabolites of five GH-releasing peptides, and for 54 prohibited agents in dried blood spots at 0.05 to 1.25 ng/mL.
- The largest peptide doping case in history produced no positive test. Thirty-four Essendon Football Club players were sanctioned by the Court of Arbitration for Sport in January 2016 over thymosin beta-4, on documentary evidence alone6.
- Topical is not a loophole. USADA states that the Prohibited List attaches no route-dependent status to peptides and growth factors, so a topical is prohibited on exactly the same terms as an injection27.
- Strict liability plus an unlabelled vial is the worst combination in this report. Presence in a sample is the violation; intent, fault and negligence need not be shown. Reviews of sports supplements have found prohibited substances in 12 to 58% of products analysed.
The two evidence files
Medicine's file on most of these compounds is close to empty. Sport's file is thick, funded and twenty years old. The same molecules appear in both.
Two institutions have taken research peptides seriously enough to write things down about them, and they are not the two you would guess.
The first is clinical medicine, and its file is thin to the point of embarrassment. The most recent independent systematic review of BPC-157 screened from inception to June 2024, found 36 includable studies, and reported 35 preclinical and one clinical — and that one was retrospective rather than randomised.
Its authors wrote that no clinical safety data were found25. There is no published randomised controlled trial of BPC-157 in a human being for any indication, and no human trial of the seven-residue fragment sold as TB-500 at all.
The second is anti-doping, and its file is the opposite. Sport identified BPC-157 in confiscated vials in 2016 and published a validated urine assay the following year7. It synthesised Ac-LKKTETQ out of a commercial TB-500 preparation, characterised it on an Orbitrap and proposed a detection strategy in the same 2012 paper9.
It has dosed volunteers with growth-hormone-releasing peptides specifically to map their urinary metabolites14. It has written these compounds into an international standard by name, and it has suspended people over them.
Twenty-eight compounds named across S0 and S2 in that table. Human randomised trials of the thing actually being sold: close to none. Published detection methods: one for every row.
Sport paid for the chemistry. Medicine never paid for the trial.
How the S0 machine works
Precaution by design. The criterion is a missing approval, not a demonstrated effect — which is exactly why a ban cannot be read as an endorsement.
Here is the deflation, stated plainly, because the rest of this report is worthless without it.
Section S0 reads, in substance: any pharmacological substance not addressed by any subsequent section of the List, and with no current approval by any governmental regulatory health authority for human therapeutic use — drugs in pre-clinical or clinical development, discontinued drugs, designer drugs, substances approved only for veterinary use — is prohibited at all times1.
Read the criterion. It is the absence of an approval. Not the presence of an effect. A compound qualifies for S0 by being unapproved and pharmacological, and by nothing else.
A completely inert unapproved peptide and a genuinely potent one meet the S0 definition identically, and the List cannot tell them apart because it was never built to.
The general inclusion standard reinforces the point. Under Article 4.3.1 of the World Anti-Doping Code, a substance is considered for the List if it meets any two of three criteria: potential to enhance performance, an actual or potential health risk to the athlete, and WADA's determination that use violates the spirit of sport28.
Two of three. Which means a substance can be prohibited on health risk plus spirit of sport with the performance criterion never satisfied at all.
That is not a theoretical gap. In 2019 a team in Sports Medicine did the obvious audit nobody had done: they went through all 23 substance classes and searched for double-blind randomised trials in trained subjects measuring relevant performance outcomes. Only 5 of 23 classes showed evidence of enhancing actual sports performance — anabolic agents, β2-agonists, stimulants, glucocorticoids and β-blockers, with growth hormone qualifying only in untrained subjects.
For 11 classes no well-designed studies existed. For the remaining six there was evidence of an absence of effect. The entire positive evidence base rested on 266 subjects across 11 studies20.
So when a vendor page tells you a peptide must work because WADA banned it, the reply is that WADA has banned 23 classes of thing and the published literature can demonstrate performance enhancement for five.
Two further consequences follow. No therapeutic use exemption is possible for an S0 substance, because a TUE requires an approved therapeutic use and by definition there is not one — USADA says exactly this about BPC-1574.
And prohibited at all times means in and out of competition, so an off-season injection is a violation waiting for a knock at the door.
BPC-157's own history makes the categorical logic visible. It was not prohibited before 2022. It was added to the 2022 List after a re-evaluation, as the first substance ever named as an example inside S02,3.
Nothing about the molecule changed that year. What changed was that enough athletes were using it that leaving it an unnamed member of a category stopped being adequate.
That is the honest reading of a naming. It is a usage signal, not an efficacy signal.
The cases
Thirty-four players, one club, one peptide, and not a single positive test. What the Essendon award establishes, and the larger thing it does not.
On 12 January 2016 the Court of Arbitration for Sport handed down its award in World Anti-Doping Agency v. Thomas Bellchambers et al., Australian Football League, Australian Sports Anti-Doping Authority, CAS 2015/A/4059.
It upheld WADA's appeal against an AFL tribunal that had cleared the players, and sanctioned 34 past and present Essendon Football Club players with two-year bans backdated to 31 March 2015 — which removed the seventeen who were still on AFL lists from the entire 2016 season6.
The substance was thymosin beta-4. The programme was the club's own 2012 supplements regime.
The detail that matters most is the one least often repeated: not one of the 34 returned an analytical positive. There was no adverse analytical finding to build on.
The case was assembled from documentary and circumstantial evidence — consent forms naming a Thymosin regimen, invoices, records of how the programme was run — and the panel reached comfortable satisfaction by treating that material as strands in a cable rather than links in a chain, expressly rejecting the tribunal's stricter approach.
Two 2012 urine samples showed elevated thymosin beta-4, but not at levels constituting failed tests.
What the award establishes. That a professional sporting institution ran an injectable peptide programme across its entire senior playing list in 2012.
That an arbitral panel, on the civil evidentiary standard, was comfortably satisfied the substance administered was thymosin beta-4. And that the consequences of an unapproved peptide programme reach the athletes rather than the people who designed it.
What it does not establish. Anything whatsoever about whether thymosin beta-4 works. No endpoint was measured, no control group existed, and the season in question was not a trial.
Essendon started 2012 with eight wins from nine and then lost ten of their last thirteen games, finishing eleventh with an 11–11 record and missing the finals — the first club to go 8–1 and miss finals since 197129.
That is not evidence the peptide failed either. It is a reminder that a season is a season and a trial is a trial, and that reading outcomes off a locker room is how this entire market got where it is.
Beyond Essendon the sanction record is quieter and more routine. USADA and UKAD both publish searchable registries of anti-doping rule violations, and cases involving growth hormone secretagogues appear in them:
USADA's own register carries a two-year sanction for an ipamorelin positive from an out-of-competition urine sample collected in 2019, with ipamorelin described there as a potent growth hormone secretagogue prohibited at all times26.
These are individual cases rather than a dataset, and we are not building a trend out of them. What they demonstrate is simpler: the assays are not theoretical. They return results, and results end careers.
The detection investment
Anti-doping laboratories have published validated assays for compounds nobody will fund an efficacy trial for. Follow the money, and it points at belief rather than at proof.
This is the section the rest of the report exists for.
Building a doping-control assay is real scientific work. It needs reference material, in-vitro metabolism studies to establish what the body actually excretes, extraction chemistry that survives a urine matrix, mass spectrometric confirmation, and validation to a standard an arbitral panel will accept.
It gets published in peer-reviewed analytical journals, and anti-doping budgets pay for it. Look at what that budget has produced.
BPC-157. In 2016 a laboratory received confiscated vials, identified BPC-157 and a mechano-growth-factor variant inside them, ran plasma metabolism experiments, found a stable metabolite that should be detectable in urine, and validated a weak cation exchange extraction with a limit of detection of 0.1 ng/mL and stability in urine for at least four days7.
In 2023 a second group used 13C and 15N-labelled BPC-157 in a nontargeted workflow, discovered nine metabolites including one from a previously unknown pathway, and validated a human urine method for the parent and five metabolites at 0.01 to 0.11 ng/mL8.
In 2026 it appears among the peptidic agents in a harmonised dried-blood-spot workflow covering 54 compounds19.
Set that against the clinical file for the same molecule: 35 preclinical studies, one retrospective clinical paper, no randomised trial, no clinical safety data25.
TB-500. In 2012 a group bought the product, found the N-terminally acetylated 17-23 fragment of thymosin beta-4 inside it, synthesised Ac-LKKTETQ independently to confirm the identification, and proposed a plasma and urine detection strategy9. The same year an equine laboratory published a full LC-MS method for the parent and its metabolites10.
A metabolite biomarker followed in 202312, simultaneous quantification in 202411, and a population-level misuse-detection strategy in 202513. Human randomised trials of Ac-LKKTETQ, the molecule all of that chemistry was built to catch: none.
The secretagogues. A 2011 method covered the GHRPs and their major metabolites in human urine15.
A 2015 study gave GHRP-1, GHRP-2, GHRP-6, hexarelin and ipamorelin nasally to volunteers and tracked what came out and for how long, finding that ipamorelin and hexarelin metabolise so extensively that their free-acid fragments outlast the parent compounds14.
Screening has since been simplified to direct urine injection with ion mobility below 2 kDa and extended upward to 10 kDa18,17, and a nano-LC Orbitrap method for GHRH analogues arrived in 202616.
That is thirteen distinct published detection methods behind the compounds in this report, several refined across more than a decade.
Here is the asymmetry in one sentence. A discipline that will not fund a phase 1 for BPC-157 will fund a mass spectrometry method that finds it at ten picograms per millilitre.
That is not medicine's judgment on the molecule. It is sport's judgment on the athletes — and the split is budgetary rather than scientific.
An assay costs a fraction of a trial, a laboratory can build one from confiscated vials and cell incubations, and the return is immediate and enforceable. A trial costs millions, needs a sponsor with something to protect, and returns nothing to anyone if the compound is off-patent and freely synthesised.
report 13Why has nobody run the trial? The economics behind the empty file.An unpatentable peptide has no sponsor, and no sponsor means no phase 3. The funding structure that decides which molecules ever get tested — and which never will.→Revealed preference
The most physiologically monitored population on earth keeps choosing these compounds. That is data. It is data about belief.
The strongest version of the argument goes like this. Elite athletes are not casual consumers. They have professional medical staff, career-scale financial incentives, direct feedback on their own performance, and a testing regime that makes every choice expensive.
When a population like that repeatedly accepts a career-ending risk for a compound, something is generating that behaviour — and because these are the most physiologically monitored humans alive, their choices carry information a general population's would not.
Take it seriously. It is also weaker than it sounds, for three reasons.
Locker rooms are not laboratories. Elite sport has a century-long record of adopting compounds that later turned out to do nothing.
The Sports Medicine audit measures it directly: for eleven of the 23 prohibited classes no well-designed studies existed, and for six there was positive evidence of no effect20. Athletes were using things in every one of those classes. Belief and effect came apart routinely.
The denominator is invisible. Sanction registries tell you who was caught. They do not tell you how many athletes used a compound and stopped because nothing happened, or how many used it alongside four other things and credited the wrong one.
There is no control arm anywhere in this dataset and there never will be. Every sanction is a case report, and case reports are the weakest evidence design there is.
The transmission mechanism is social, not empirical. Essendon is the cleanest demonstration of this in the record, which is why it belongs in this section as much as the last one.
A club-wide, staff-administered, professionally organised peptide programme was run on 34 players — and its rationale came from inside the organisation rather than from a literature that did not exist. Thirty-four athletes taking a compound is not thirty-four independent judgments. It is one judgment, executed thirty-four times.
The honest reading, then. Elite-sport behaviour measures how confidently a claim circulates in a high-stakes, information-dense environment. That is genuinely useful, and worth more than a supplement forum. It is not a measurement of the molecule.
It is a belief thermometer with excellent resolution. It measures the room, not the compound.
If you compete
Strict liability, sub-nanogram detection limits, and a research market that sells unlabelled variance. The three combine badly.
Everything above is analysis. This part is operational, and if you are a tested athlete it is the only part that will matter to you.
Strict liability. Under Article 2.1.1 of the World Anti-Doping Code it is each athlete's personal duty to ensure that no prohibited substance enters their body, and athletes are responsible for any prohibited substance or its metabolites or markers found present in their samples.
It is not necessary that intent, fault, negligence or knowing use be demonstrated to establish the violation28. You do not get to explain. The sample explains for you.
The detection floor is sub-nanogram. The BPC-157 methods above run to 0.01 ng/mL, and the dried-blood-spot workflow validates at 0.05 to 1.25 ng/mL across 54 compounds19. A trace is enough.
No route changes the answer either — USADA states directly that the Prohibited List attaches no route-dependent status to peptides and growth factors, so topical use of a listed peptide is just as prohibited as an injectable or oral form27.
And contamination is not a rare accident. A review of sports supplements analysed for WADA-banned substances reported contamination rates between 12 and 58% across the studies it included21, and the association between supplement use and positive tests has been documented for two decades22.
A 2021 forensic analysis of 110 pharmaceutical and supplement products seized from a black market found contents that did not reliably correspond to their labelling24. Anti-doping bodies have responded by building behavioural frameworks around risk-minimising supplement use, precisely because certification reduces risk without eliminating it23.
Combine those three with a research-market vial and count the failure modes. The compound on the label may be prohibited. Something else in the vial that is not on the label may also be prohibited.
The quantity may not be what the label says. Under strict liability every one of those is your problem, adjudicated on an assay with a picogram-scale detection limit.
That is why the certificate matters more here than anywhere else on this site. Whether a peptide works is the question the rest of our reports answer. Whether the vial contains what the label claims is a separate failure, and for a tested athlete it is the more dangerous one.
reader skillsBefore the claim, the paperwork. How to read a certificate of analysis.The five measures a real COA carries, which ones most certificates quietly skip, and how to verify one directly with the laboratory — in five minutes.→FAQ
Is BPC-157 banned by WADA?
Yes. BPC-157 is prohibited at all times under section S0, Non-Approved Substances, and it was added to the 2022 Prohibited List — the first substance ever written into S0 as a named example. S0 covers any pharmacological substance with no current approval by any governmental regulatory health authority for human therapeutic use.
Because there is no approved therapeutic use anywhere in the world, there is no basis on which a therapeutic use exemption could be granted for it.
Prohibited at all times means in competition and out of competition, and the ban is not route-dependent: USADA states that the Prohibited List attaches no route-dependent status to peptides and growth factors, so an oral, a nasal spray and an injection are all treated the same way.
Does a WADA ban mean a peptide works?
No, and section S0 is designed so that it cannot mean that. S0 prohibits a substance because it lacks an approval for human therapeutic use, not because anyone has shown it enhances performance.
Under Article 4.3.1 of the World Anti-Doping Code a substance needs to meet only two of three criteria to be considered for the List — performance potential, health risk, and violation of the spirit of sport — so a compound can be listed on health risk plus spirit of sport with the performance criterion never satisfied.
A 2019 review in Sports Medicine assessed the entire List and found that only 5 of 23 substance classes had double-blind randomised evidence of enhancing actual sports performance in trained subjects.
For 11 classes no well-designed studies existed at all, and for six there was evidence of an absence of effect. The ban is a precaution taken under uncertainty. It is not a verdict.
Can I get banned for GHK-Cu face cream?
On the published guidance, a cosmetic containing GHK is not the problem — USADA lists tripeptide-1, that is non-palmitoylated GHK, among cosmetic peptide ingredients that are not prohibited.
What is prohibited in cosmetics is growth factors: FGF, IGF-1, VEGF and PDGF are named on the List, and USADA is explicit that topical use of a growth factor or peptide is just as prohibited as an injectable or oral form, because the List attaches no route-dependent status to this class.
So read your skincare ingredient panel for growth factors rather than for copper peptides. Two cautions remain. Injected GHK-Cu is a different question from a cream, since an injectable copper peptide is an unapproved pharmacological substance and S0 is written broadly.
And strict liability means the athlete carries the consequence of whatever is actually in the product, not what the label claims. If you compete, check the specific product on Global DRO or with your national anti-doping organisation rather than relying on a category answer.
How long do peptides stay detectable?
Honestly: the published detection windows are thin, and most numbers circulating online are invented. The best human data we located comes from a 2015 study in which five growth-hormone-releasing peptides were each given to a single volunteer nasally and urine was collected for two days.
A GHRP-1 metabolite was detectable up to 27 hours, GHRP-2 and two of its metabolites up to 47 hours, and GHRP-6 up to 23 hours with its metabolites detectable for only 12.
That is one volunteer per compound, by a nasal route, so treat it as an order of magnitude rather than a rule.
For BPC-157 no human excretion-window study exists at all; what exists is an assay with a limit of detection of 0.1 ng/mL and a finding that the compound is stable in urine for at least four days, plus a 2023 human urine method covering the parent and five metabolites down to 0.01 ng/mL. Detection limits have moved into the sub-nanogram range in both urine and dried blood spots, which means the practical question is not how long a compound is present but how little of it a modern laboratory needs.
Why does sport ban what medicine ignores?
Because the two institutions are answering different questions with different budgets. Medicine asks whether a compound helps a patient, and answering that costs a trial that someone has to fund — which is why an off-patent, freely synthesised peptide with no sponsor gets no trial.
Sport asks whether athletes are using something, and answering that costs an assay. An assay is far cheaper than a phase 3, an anti-doping laboratory can build one from confiscated vials and in-vitro metabolism work, and the return on it is immediate.
So the incentive structures point in opposite directions on the same molecule. The result is the asymmetry this report is about: there is a validated urine method for BPC-157 published in 2017 and refined in 2023, and there is still no published randomised controlled trial of BPC-157 in humans for any indication.
Sport's file is thick because catching people is affordable. Medicine's file is empty because proving things is not.
References
All PubMed identifiers below were retrieved and title-matched before publication. WADA's own Prohibited List PDF is served behind a challenge that blocks automated retrieval, so the S0 and S2 text quoted here was confirmed against WADA's published list page and news releases and against the national anti-doping organisations that reproduce the standard.
Where a claim could not be confirmed against a primary source, it has been softened or omitted rather than cited loosely.
- World Anti-Doping Agency, The Prohibited List — section S0, Non-Approved Substances, prohibited at all times — wada-ama.org
- WADA, 2022 Prohibited List and Summary of Major Modifications — BPC-157 added as the first named example within S0 — wada-ama.org
- USADA, Athlete Advisory: Explanation of Key Changes on the 2022 Prohibited List — usada.org
- USADA, BPC-157: Experimental Peptide Creates Risk for Athletes — usada.org
- World Anti-Doping Agency, The Prohibited List — section S2, Peptide Hormones, Growth Factors, Related Substances and Mimetics [S2.2 GHRH analogues, GH secretagogues and GHRPs; S2.3 growth factors including thymosin-β4 and its derivatives] — wada-ama.org
- CAS 2015/A/4059, World Anti-Doping Agency v. Thomas Bellchambers et al., Australian Football League, Australian Sports Anti-Doping Authority — award of 12 January 2016; 34 players sanctioned, two-year bans backdated to 31 March 2015
- Cox HD et al. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal 2017;9:1490-1498 — PMID 28035768
- Tian T et al. Stable isotope labeling-based nontargeted strategy for characterization of the in vitro metabolic profile of a novel doping BPC-157 in doping control by UHPLC-HRMS. Molecules 2023;28:7345 — PMID 37959764
- Esposito S et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal 2012;4:733-738 — PMID 22962027
- Ho EN et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A 2012;1265:57-69 — PMID 23084823
- Rahaman KA et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive Orbitrap MS/MS. J Chromatogr B 2024;1235:124033 — PMID 38382158
- Rahaman KA et al. Detection and quantification of the metabolite Ac-Tβ[1-14] in in vitro experiments and urine of rats treated with Ac-Tβ4. Drug Test Anal 2023;15:1454-1467 — PMID 37515313
- Delcourt V et al. Equine doping controls of thymosin β4: a population study and strategy for misuse detection. Drug Test Anal 2025;17:1071-1077 — PMID 39314109
- Semenistaya E et al. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, hexarelin, and ipamorelin. Drug Test Anal 2015;7:919-925 — PMID 25869809
- Thomas A et al. Determination of growth hormone releasing peptides [GHRP] and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry. Anal Bioanal Chem 2011;401:507-516 — PMID 21298258
- Uçaktürk E et al. Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/Orbitrap mass spectrometry. J Pharm Biomed Anal 2026;268:117207 — PMID 41138283
- Thomas A et al. Chromatographic-mass spectrometric analysis of peptidic analytes [2-10 kDa] in doping control urine samples. J Mass Spectrom 2024;59:e4996 — PMID 38197510
- Thomas A et al. Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry. J Sep Sci 2016;39:333-341 — PMID 26578461
- Mazzarino M et al. Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices. Analyst 2026;151:4398-4413 — PMID 42328738
- Heuberger JAAC, Cohen AF. Review of WADA prohibited substances: limited evidence for performance-enhancing effects. Sports Med 2019;49:525-539 — PMID 30411235
- Martínez-Sanz JM et al. Intended or unintended doping? A review of the presence of doping substances in dietary supplements used in sports. Nutrients 2017;9:1093 — PMID 28976928
- Maughan RJ. Contamination of dietary supplements and positive drug tests in sport. J Sports Sci 2005;23:883-889 — PMID 16195040
- Backhouse SH et al. A behaviourally informed approach to reducing the risk of inadvertent anti-doping rule violations from supplement use. Sports Med 2023;53:67-84 — PMID 37801267
- Fabresse N et al. Analysis of pharmaceutical products and dietary supplements seized from the black market among bodybuilders. Forensic Sci Int 2021;322:110771 — PMID 33838562
- Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J 2025;21:485-495 — PMID 40756949
- USADA, published sanctions register — anti-doping rule violations including a two-year sanction for an ipamorelin positive from an out-of-competition sample collected in 2019 — usada.org
- USADA, Peptides and Growth Factors in Cosmetics: Are They Banned? — usada.org
- World Anti-Doping Code, Article 2.1.1 [strict liability] and Article 4.3.1 [criteria for inclusion on the Prohibited List] — wada-ama.org
- 2012 Australian Football League season, Essendon Football Club — final ladder position 11th, 11 wins and 11 losses, no finals appearance after an 8–1 start
Inside Your Peptides is independent. We sell nothing. We disclose every referral relationship where one exists. The report above contains no vendor link; the sourcing desk that follows it is separate, and disclosed. Grades and rankings follow the published criteria in our editorial policy, never referral terms.
This report is for research and educational purposes only. It is not medical advice. Nothing here is a dosing recommendation or a suggestion to obtain, possess or administer any compound. Several substances discussed are unapproved, prescription-only, or subject to active regulatory proceedings. Speak to a qualified clinician before making any decision about your health.